Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments
Frank Loganzo,Xingzhi Tan,Matthew Sung,Guixian Jin,Jeremy S. Myers,Eugene Melamud,Fang Wang,Veronica Diesl,Maximillian T. Follettie,Sylvia Musto,My-Hanh Lam,William T. Hu,Manoj Charati,Kiran Khandke,Kenny Sung Kyoo Kim,Mike Cinque,Judy Lucas,Edmund I. Graziani,Andreas Maderna,Christopher J. O’Donnell,Kim Arndt,Hans-Peter Gerber +21 more
TLDR
In this article, a trastuzumab-maytansinoid ADC (TM-ADC) was applied to breast cancer cell lines, and the authors found that the ADC-resistant cells, 361-TM and JIMT1-TM, were characterized by cytotoxicity, proteomic, transcriptional and other profiling.Abstract:
Antibody-drug conjugates (ADC) are emerging as clinically effective therapy. We hypothesized that cancers treated with ADCs would acquire resistance mechanisms unique to immunoconjugate therapy and that changing ADC components may overcome resistance. Breast cancer cell lines were exposed to multiple cycles of anti-Her2 trastuzumab-maytansinoid ADC (TM-ADC) at IC80 concentrations followed by recovery. The resistant cells, 361-TM and JIMT1-TM, were characterized by cytotoxicity, proteomic, transcriptional, and other profiling. Approximately 250-fold resistance to TM-ADC developed in 361-TM cells, and cross-resistance was observed to other non-cleavable-linked ADCs. Strikingly, these 361-TM cells retained sensitivity to ADCs containing cleavable mcValCitPABC-linked auristatins. In JIMT1-TM cells, 16-fold resistance to TM-ADC developed, with cross-resistance to other trastuzumab-ADCs. Both 361-TM and JIMT1-TM cells showed minimal resistance to unconjugated mertansine (DM1) and other chemotherapeutics. Proteomics and immunoblots detected increased ABCC1 (MRP1) drug efflux protein in 361-TM cells, and decreased Her2 (ErbB2) in JIMT1-TM cells. Proteomics also showed alterations in various pathways upon chronic exposure to the drug in both cell models. Tumors derived from 361-TM cells grew in mice and were refractory to TM-ADC compared with parental cells. Hence, acquired resistance to trastuzumab-maytansinoid ADC was generated in cultured cancer cells by chronic drug treatment, and either increased ABCC1 protein or reduced Her2 antigen were primary mediators of resistance. These ADC-resistant cell models retain sensitivity to other ADCs or standard-of-care chemotherapeutics, suggesting that alternate therapies may overcome acquired ADC resistance. Mol Cancer Ther; 14(4); 952-63. ©2015 AACR.read more
Citations
More filters
Journal Article
Novel mechanisms of glucocorticoid resistance in childhood acute lymphoblastic leukemia.
TL;DR: It is reported that PTEN activation contributes to trastuzumab's antitumor activity and PTEN deficiency is a powerful predictor for trastzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance.
Journal ArticleDOI
Strategies and challenges for the next generation of antibody–drug conjugates
TL;DR: Strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues are discussed.
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi,Cristina Saura,Toshinari Yamashita,Yeonhee Park,Sung Bae Kim,Kenji Tamura,Fabrice Andre,Hiroji Iwata,Yoshinori Ito,Junji Tsurutani,Junji Tsurutani,Joohyuk Sohn,Neelima Denduluri,Christophe Perrin,Kenjiro Aogi,Eriko Tokunaga,Seock-Ah Im,Keun Seok Lee,Sara A. Hurvitz,Javier Cortes,Caleb Lee,Shuquan Chen,Lin Zhang,Javad Shahidi,Antoine Yver,Ian E. Krop +25 more
TL;DR: Tastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer and requires attention to pulmonary symptoms and careful monitoring.
Journal ArticleDOI
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani,Tetsuo Aida,Katsunobu Hagihara,Junko Yamaguchi,Chiaki Ishii,Harada Naoya,Masako Soma,Hiromi Okamoto,Masataka Oitate,Shingo Arakawa,Takehiro Hirai,Ryo Atsumi,Takashi Nakada,Ichiro Hayakawa,Yuki Abe,Toshinori Agatsuma +15 more
TL;DR: DS-8201a exhibited a potent antitumor activity in a broad selection of HER2-positive models and favorable pharmacokinetics and safety profiles and will be a valuable therapy with a great potential to respond to T-DM1–insensitive Her2- positive cancers and low HER2–expressing cancers.
Journal ArticleDOI
Antibody-Drug Conjugates: A Comprehensive Review
TL;DR: This review provides an overview of the systemic evaluation of each component of an ADC design, improved understanding of the mechanism of action of ADC, and mechanistic pathways involved in ADC resistance and various strategies to optimize ADC design.
References
More filters
Journal ArticleDOI
Cancer drug resistance: an evolving paradigm
TL;DR: There are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Journal ArticleDOI
Targeting multidrug resistance in cancer
Gergely Szakács,Jill K. Paterson,Joseph A. Ludwig,Catherine Booth-Genthe,Michael M. Gottesman +4 more
TL;DR: Various approaches to combating multidrug-resistant cancer are described, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Journal ArticleDOI
Modes of resistance to anti-angiogenic therapy.
Gabriele Bergers,Douglas Hanahan +1 more
TL;DR: Emerging data support a proposition that two modes of unconventional resistance underlieAngiogenesis inhibitors targeting the vascular endothelial growth factor signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers.
Journal ArticleDOI
Targeting cancer with small molecule kinase inhibitors
TL;DR: This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors, and discusses the current challenges in the field.
Journal ArticleDOI
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Yoichi Nagata,Keng-Hsueh Lan,Xiaoyan Zhou,Ming Tan,Francisco J. Esteva,Aysegul A. Sahin,Kristine S. Klos,Ping Li,Brett P. Monia,Nina T. Nguyen,Gabriel N. Hortobagyi,Mien Chie Hung,Dihua Yu +12 more
TL;DR: In this paper, PTEN activation contributes to trastuzumab's antitumor activity and PI3K inhibitors rescued PTEN loss-induced trastusumab resistance.